TD Cowen raises Moderna stock price target to $90 on cancer outlook
TD Cowen raised its price target on Moderna (MRNA) to $90 from $40, maintaining a Hold rating. The stock trades near its 52-week high at $242, up 721% YTD. The firm updated its financial model, estimating peak INT profit of $3.4B in 2035 for Moderna's cancer treatments. Moderna will join the Nasdaq-100 Index on October 9. Analysts from Bernstein and UBS maintained their ratings and price targets.
How this was made
The 30-second read
Why it matters
The target reduction signals a bearish stance despite recent index inclusion and ongoing legal challenges.
Market read
Analyst price‑target cut is a fresh, material development that could drive short‑term sell pressure on MRNA.
What to watch
Upcoming melanoma trial results could offset short‑term price pressure if data are positive.
Background
TD Cowen updated its financial model ahead of Moderna's Q3 earnings, citing adjuvant melanoma and lung cancer opportunities.
Ticker impact
TD Cowen raised its price target on Moderna (MRNA) to $90 from $40, far below the current $242 price, indicating a bearish outlook.
likely downward pressure as investors price in the $90 target versus current levels
The new target is more than 60% below the market price, prompting potential sell-offs.
Market effects
Biotech sector may see broader risk reassessment as a high‑profile mRNA company receives a steep target cut.
US biotech equities could face short‑term pressure.
Limited to investors tracking Moderna and related mRNA peers.
Counterpoint
Some investors may view the target cut as an overreaction given long‑term pipeline potential.
Key entities
- companyModerna Inc.
Biotech firm developing mRNA therapeutics.
